Weekly MI Briefing — Cosentyx

Week ending 30 August 2026

1. This week’s recurring question themes

• Comparisons and treatment choice (~7 brand questions): People asked how to frame Cosentyx versus Taltz, Humira, Stelara, and Enbrel; whether it is “stronger”; and what differences matter when switching from another IL-17 biologic. Common needs include neutral comparison language, onset, tolerability, dosing, and practical access.
• Label, safety, and special populations (~7 PI questions): Questions covered pregnancy/breastfeeding and infant live vaccines, renal/hepatic impairment, active infection, contraindications, boxed warnings, and monitoring/TB screening.
• Dosing and administration (~3 questions): Users asked for plaque-psoriasis loading and maintenance dosing, device selection, refrigeration, and injection steps. Dosing answers were short in places but materially inconsistent on when maintenance begins.
• Interactions and vaccines (1 PI question): A specific rifampin/polypharmacy question asked about drug interactions and vaccines.
• Substitution/access (2 questions): Users asked about pharmacy substitution with a generic or biosimilar and about switching between biologics. No compounded-product question appeared this week.

2. Where no consistent answer currently exists

These are real MI-relevant questions where a person may receive different answers depending on the AI answer variant:

• Pregnancy/breastfeeding and infant live vaccines: In the question, “Can Cosentyx be used during pregnancy or breastfeeding…?”, contraindication/not-recommended language appeared in only 2 of 6 answers. The question specifically requests label-level guidance, so a single approved response should distinguish label wording from clinical interpretation.
• Administration and handling: For “How do you administer Cosentyx… and what are the steps around taking it out of the fridge?”, answers varied on whether to include infection and allergy precautions and referred generally to device instructions. This supports a device-specific administration SRD or FAQ.
• Active infection: For “Can I start or continue Cosentyx…?”, contraindication language appeared in only 1 of 6 answers, despite all answers discussing infection. The distinction between contraindication, precaution, and clinician-directed holding is not consistently surfaced.
• Interactions/vaccines: In the rifampin question, contraindication/vaccine language appeared in 4 of 6 answers. The answers generally said there is no direct rifampin interaction, but a consistent interaction-and-vaccine response is needed.
• Boxed-warning status: The warning question produced a direct contradiction: most answers said there is no boxed warning, while one stated that Cosentyx carries one.

3. Off-label and substitution questions

• Off-label: No off-label question appeared this week and the tally fell to zero from 3 the prior week. There is no current evidence that AI coverage is addressing an active off-label MI need; monitor rather than create a new SRD solely on this week’s data.
• Biosimilar/generic substitution: The pharmacy question generated six answers, but responses ranged from “biosimilars” to suggestions that a different same-class brand may be substituted; one answer stated Cosentyx is “often available through biosimilar products.” This is a thin, potentially confusing area and does not appear consistently covered by existing content.
• Compounded substitution: No compounded question or signal was present.

4. Trend across weeks

Question volume remains fixed at 20 distinct questions weekly, but inconsistency flags rose to 29, the highest in the six-week series, up from 26 last week. Safety/special-population themes recur every week, as do comparison questions involving Humira, Stelara, Enbrel, and Taltz. Current category counts are lower than last week, but the persistent inconsistency pattern—not raw tag volume—is the stronger MI-content signal.

5. Recommended actions

1. Create/update an SRD: pregnancy, lactation, and infant live-vaccine guidance. Highest priority due to the specific label question and 2/6 inconsistency.
2. Create/update a device administration and storage FAQ/SRD. Include pen versus syringe, infusion scope, refrigeration, inspection, and missed/handled-dose questions.
3. Review the infection/contraindications/monitoring SRD for currency and terminology. Harmonize “active infection,” “hold,” “do not start,” TB screening, IBD, and hypersensitivity wording.
4. Create a substitution FAQ covering generic versus biosimilar, interchangeability, payer/pharmacy substitution, and compounded products. The six biosimilar answers are not consistently grounded.
5. Review, rather than create, a neutral-comparison SRD. Comparison volume is sustained, but the immediate need is consistent, indication-specific language rather than a new safety document.